ATE293988T1 - Pharmazeutische zusammensetzungen mit botulinum toxin - Google Patents

Pharmazeutische zusammensetzungen mit botulinum toxin

Info

Publication number
ATE293988T1
ATE293988T1 AT01905436T AT01905436T ATE293988T1 AT E293988 T1 ATE293988 T1 AT E293988T1 AT 01905436 T AT01905436 T AT 01905436T AT 01905436 T AT01905436 T AT 01905436T AT E293988 T1 ATE293988 T1 AT E293988T1
Authority
AT
Austria
Prior art keywords
pharmaceutical compositions
compositions containing
botulinum toxin
containing botulinum
toxin
Prior art date
Application number
AT01905436T
Other languages
German (de)
English (en)
Inventor
Terrence J Hunt
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23988236&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE293988(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ATE293988T1 publication Critical patent/ATE293988T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
AT01905436T 2000-02-08 2001-02-05 Pharmazeutische zusammensetzungen mit botulinum toxin ATE293988T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50014700A 2000-02-08 2000-02-08
PCT/US2001/003641 WO2001058472A2 (en) 2000-02-08 2001-02-05 Botulinum toxin pharmaceutical compositions

Publications (1)

Publication Number Publication Date
ATE293988T1 true ATE293988T1 (de) 2005-05-15

Family

ID=23988236

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01905436T ATE293988T1 (de) 2000-02-08 2001-02-05 Pharmazeutische zusammensetzungen mit botulinum toxin
AT04029089T ATE519494T1 (de) 2000-02-08 2001-02-05 Pharmazeutische zusammensetzungen mit botulinum- toxin

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT04029089T ATE519494T1 (de) 2000-02-08 2001-02-05 Pharmazeutische zusammensetzungen mit botulinum- toxin

Country Status (19)

Country Link
US (2) US20020064536A1 (enExample)
EP (4) EP1586329A1 (enExample)
JP (7) JP2003522154A (enExample)
KR (3) KR100753765B1 (enExample)
CN (2) CN1258379C (enExample)
AR (1) AR027391A1 (enExample)
AT (2) ATE293988T1 (enExample)
AU (2) AU3331501A (enExample)
BR (1) BR0108173A (enExample)
CA (3) CA2400318C (enExample)
CY (1) CY1108007T1 (enExample)
DE (2) DE60110372T2 (enExample)
DK (3) DK1514556T3 (enExample)
ES (3) ES2275992T5 (enExample)
MX (1) MXPA02007519A (enExample)
NZ (2) NZ530779A (enExample)
PT (3) PT1253932E (enExample)
TW (2) TWI282739B (enExample)
WO (1) WO2001058472A2 (enExample)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
JP2003522154A (ja) * 2000-02-08 2003-07-22 アラーガン、インコーポレイテッド ボツリヌス毒素医薬組成物
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
DE10035156A1 (de) * 2000-07-19 2002-02-07 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Proteinkomplex als Vehikel für oral verfügbare Protein-Arzneimittel
US6423319B1 (en) * 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
DE10149030A1 (de) * 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
US7140371B2 (en) * 2002-03-14 2006-11-28 Allergan, Inc. Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins
JPWO2003082315A1 (ja) * 2002-03-29 2005-07-28 財団法人化学及血清療法研究所 筋緊張亢進疾患治療剤
US7691394B2 (en) 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
US7459164B2 (en) 2002-05-28 2008-12-02 Botulinum Toxin Research Associates, Inc. Composition for therapeutic and cosmetic botulinum toxin
US7238357B2 (en) * 2002-11-05 2007-07-03 Allergan, Inc. Methods for treating ulcers and gastroesophageal reflux disease
EP1594523B1 (en) 2002-12-20 2009-03-25 Botulinum Toxin Research Associates, Inc. Pharmaceutical compositions comprising botulinum toxin and human serum albumin
ATE404175T1 (de) * 2003-03-31 2008-08-15 Alza Corp Nicht wässrige einphasige visköse vehikel und formulierungen die diese vehikel verwenden
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
FR2855177B1 (fr) * 2003-05-23 2005-07-08 Raymond Robert Composition contenant des acides nucleiques lyophilises en presence de collagene et de disaccharides
US7148041B2 (en) 2003-09-25 2006-12-12 Allergan, Inc. Animal product free media and processes for obtaining a botulinum toxin
US7452697B2 (en) 2003-09-25 2008-11-18 Allergan, Inc. Chromatographic method and system for purifying a botulinum toxin
US7160699B2 (en) 2003-09-25 2007-01-09 Allergan, Inc. Media for clostridium bacterium and processes for obtaining a clostridial toxin
US20050191321A1 (en) * 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
US9078892B2 (en) * 2004-02-26 2015-07-14 Allergan, Inc. Methods for treating pain and for treating a medication overuse disorder
US20100266638A1 (en) 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US7691381B2 (en) * 2004-04-15 2010-04-06 Allergan, Inc. Stabilized biodegradable neurotoxin implants
RU2255761C1 (ru) * 2004-07-01 2005-07-10 Общество с ограниченной ответственностью "Токсины и сопутствующие продукты" Препарат для лечения мышечных дистоний из токсина культуры clostridium botulinum и способ его получения
GB2416122A (en) 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
EP2266599B1 (en) 2004-07-26 2014-04-16 Merz Pharma GmbH & Co. KGaA Therapeutic composition with a botulinum neurotoxin
EP3210620A1 (en) 2004-08-04 2017-08-30 Ipsen Biopharm Limited Pharmaceutical composition containing botulinum neurotoxin a2
US20080102090A1 (en) * 2004-08-04 2008-05-01 Naveed Panjwani Pharmaceutical Compositon Containing Botulinum Neurotoxin A2
US8192979B2 (en) 2005-01-03 2012-06-05 Botulinum Toxin Research Associates, Inc. Compositions, methods and devices for preparing less painful Botulinum toxin formulations
US7727537B2 (en) 2005-02-14 2010-06-01 Dpm Therapeutics Corp. Stabilized compositions for topical administration and methods of making same
US7838011B2 (en) 2005-02-14 2010-11-23 Pankaj Modi Stabilized protein compositions for topical administration and methods of making same
US9180081B2 (en) * 2005-03-03 2015-11-10 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
KR20070116710A (ko) 2005-03-03 2007-12-11 알러간, 인코포레이티드 보툴리눔 독소를 정제하기 위한 동물 산물이 없는 시스템및 프로세스
US8926991B2 (en) * 2005-06-14 2015-01-06 Botulinum Toxin Research Associates, Inc. Botulinum toxin and the treatment of primary disorders of mood and affect
US20230390368A1 (en) * 2005-06-27 2023-12-07 Revance Therapeutics, Inc. Methods of Treating Cervical Dystonia in a Subject Having Underlying Condition(s)
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US8323666B2 (en) * 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
FR2889936B1 (fr) 2005-09-01 2007-12-21 Sod Conseils Rech Applic Methode pour quantifier une neurotoxine cholinergique dans un echantillon
US7744904B1 (en) 2005-09-26 2010-06-29 B.B. Scientific L.L.C. Stabilization of Clostridium botulinum neurotoxin complex
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
AU2013202329B2 (en) * 2005-10-06 2016-04-14 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
US8137677B2 (en) 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
WO2007044809A2 (en) * 2005-10-11 2007-04-19 Botulinum Toxin Research Associates, Inc. Albumin-free botulinum toxin based pharmaceutical compositions containing a hyaluronidase and methods of use
CN100384993C (zh) * 2005-11-02 2008-04-30 浙江大学 提高地衣芽孢杆菌zjuel31410弹性蛋白酶稳定性的方法
FR2896693B1 (fr) * 2006-01-27 2008-03-14 Sod Conseils Rech Applic Composition comprenant plusieurs toxines botuliques
DE102006019447A1 (de) * 2006-04-24 2007-10-25 Dressler, Dirk, Dr. Markierung von Botulinum Toxin
ES2386972T3 (es) 2006-05-31 2012-09-10 Genzyme Corporation Uso de polisacáridos para la estimulación de la actividad enzimática
FR2902341B1 (fr) * 2006-06-16 2011-02-25 Scras Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
FR2907680B1 (fr) 2006-10-27 2012-12-28 Scras Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur induite par au moins un agent anti-cancereux
FR2910327B1 (fr) 2006-12-22 2013-04-26 Scras Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
CA2677202A1 (en) * 2006-12-29 2008-07-10 Revance Therapeutics, Inc. Compositions and methods of topical application and transdermal delivery of botulinum toxins stabilized with polypeptide fragments derived from hiv-tat
GB0705245D0 (en) 2007-03-19 2007-04-25 Stabilitech Ltd Stable biological products
CA2690218C (en) * 2007-06-13 2017-02-28 Csl Behring Gmbh Use of vwf stabilized fviii preparations and of vwf preparations without fviii for extravascular administration in the therapy and prophylactic treatment of bleeding disorders
RU2440825C2 (ru) * 2007-07-10 2012-01-27 Меди-Токс, Инк. Жидкая фармацевтическая композиция ботулинического токсина
US7473429B1 (en) * 2007-07-27 2009-01-06 Renfroe J Ben Method for treatment of laminitis in animals
JP2009132686A (ja) * 2007-10-26 2009-06-18 Okayama Univ ボツリヌス毒素由来のポリペプチド及びボツリヌス毒素の検出方法
EP2072039A1 (en) 2007-12-21 2009-06-24 Merz Pharma GmbH & Co.KGaA Use of a neurotoxic component of Clostridium botulinum toxin complex to reduce or prevent side effects
EP2072057A1 (en) 2007-12-21 2009-06-24 Merz Pharma GmbH & Co.KGaA Early administration of Botulinum toxin in the treatment of cerebrovascular event and spinal cord injury
US9107815B2 (en) 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
FR2930447B1 (fr) 2008-04-25 2010-07-30 Sod Conseils Rech Applic Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique
US20100034854A1 (en) * 2008-08-05 2010-02-11 Solstice Neurosciences, Inc. Compositions of activated botulinum holotoxin type B (150 KD)
EP2315598A1 (en) * 2008-08-05 2011-05-04 Solstice Neurosciences, Inc. Compositions of activated botulinum toxin type b
US20100112005A1 (en) * 2008-11-03 2010-05-06 Solstice Neurosciences, Inc. Compositions of activated botulinum toxin type B
US20100112006A1 (en) * 2008-11-03 2010-05-06 Solstice Neurosciences, Inc. Compositions of activated botulinum holotoxin type B (150 kD)
EP2364168A1 (en) 2008-12-04 2011-09-14 Botulinum Toxin Research Associates, Inc. Extended length botulinum toxin formulation for human or mammalian use
CN105833254A (zh) * 2008-12-10 2016-08-10 阿勒根公司 梭菌毒素药物组合物
RU2011125775A (ru) 2008-12-31 2013-02-10 Реванс Терапьютикс, Инк. Составы на основе ботулотоксина для инъекции
US20100184685A1 (en) * 2009-01-19 2010-07-22 Zavala Jr Gerardo Systems and methods for treating post- operative, acute, and chronic pain using an intra-muscular catheter administrated combination of a local anesthetic and a neurotoxin protein
EP2248518B1 (en) 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
KR101975051B1 (ko) 2009-06-25 2019-05-03 레반스 테라퓨틱스, 아이엔씨. 알부민­불포함 보툴리눔 독소 제제
US8129139B2 (en) 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
EP2544658A2 (en) * 2010-03-12 2013-01-16 SurModics, Inc. Injectable drug delivery system
JP5769379B2 (ja) * 2010-03-17 2015-08-26 グンゼ株式会社 Ｄａｎｃｅタンパク質溶液
EP2624801A1 (en) * 2010-10-06 2013-08-14 Allergan, Inc. System for storage and subsequent handling of botulinum toxin
US9173944B2 (en) 2010-10-12 2015-11-03 Merz Pharma Gmbh & Co. Kgaa Formulation suitable for stabilizing proteins, which is free of mammalian excipients
US8920795B2 (en) * 2011-03-31 2014-12-30 Medy-Tox Inc. Lyophilized preparation of botulinum toxin
KR101135486B1 (ko) 2011-05-25 2012-04-13 함종욱 보툴리눔 에이형 독소의 액상제품
US9393291B2 (en) 2012-04-12 2016-07-19 Botulinum Toxin Research Associates, Inc. Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US9901627B2 (en) 2014-07-18 2018-02-27 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
CN104189891B (zh) * 2014-08-15 2016-03-30 北京四环生物制药有限公司 一种不含人血清蛋白的重组人促红素制剂
KR102557798B1 (ko) * 2014-12-23 2023-07-19 메르츠 파마 게엠베하 운트 코. 카가아 보툴리눔 독소 사전충전된 용기
CA2974450C (en) 2015-02-03 2024-01-09 Merz Pharma Gmbh & Co. Kgaa Botulinum toxin prefilled container
EP3368071B1 (en) 2015-10-29 2022-01-26 ReVance Therapeutics, Inc. Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect
WO2017188618A1 (en) * 2016-04-26 2017-11-02 Korea Prime Pharm Co., Ltd. A novel composition comprising botulinum toxin
PT3679946T (pt) * 2016-05-27 2022-01-14 Ipsen Biopharm Ltd Formulação líquida de neurotoxina estabilizada com triptofano ou tirosina
WO2018038301A1 (en) * 2016-08-26 2018-03-01 Hugel Inc. Stabilized liquid formulation of botulinum toxin and preparation method thereof
WO2018038585A1 (ko) * 2016-08-26 2018-03-01 주식회사 에이비바이오 보툴리눔 독소 및 안정화제를 포함하는 액상 제형 및 이의 제조방법
PT3432916T (pt) 2016-09-13 2019-11-20 Allergan Inc Composições de toxina clostrídica não-proteica estabilizadas
EP3675900A4 (en) 2017-08-28 2021-05-05 Revance Therapeutics, Inc. Transmucosal botulinum toxin compositions, kits, and methods for treating bladder disorders
KR20190038292A (ko) * 2017-09-29 2019-04-08 한국프라임제약주식회사 효능 지속시간이 연장된 보툴리눔 독소 조성물
CN111417420B (zh) * 2017-11-17 2024-02-02 瑞典孤儿比奥维特鲁姆有限公司 带有离子交换材料的注射器组件
KR102063475B1 (ko) * 2018-02-22 2020-01-09 주식회사 에이비바이오 보툴리눔 독소, 안정화제, 및 국소마취제를 포함하는 액상 제형 및 이의 제조방법
KR102259423B1 (ko) 2018-11-30 2021-06-02 주식회사 휴온스바이오파마 보툴리눔 독소의 안정화 액상 조성물
WO2020111852A1 (ko) 2018-11-30 2020-06-04 주식회사 휴온스글로벌 보툴리눔 독소의 안정화 액상 조성물
JP2023515918A (ja) 2020-01-13 2023-04-17 デュレクト コーポレーション 不純物が低減された徐放性薬物送達システム及び関連の方法
KR102404217B1 (ko) * 2020-04-08 2022-06-02 (주)메디톡스 토출 속도 조절이 용이하고 안정한 보툴리눔 독소 사전충전된 주사기 제형
CN120789405A (zh) * 2020-04-08 2025-10-17 玫帝托克斯股份有限公司 一种易于控制排出速度且稳定的肉毒杆菌毒素预填充式注射器剂型
CN111675754A (zh) * 2020-05-19 2020-09-18 四川一埃科技有限公司 一种肉毒毒素蛋白晶体结构及晶体制备方法和解析方法
JP2024503402A (ja) 2021-01-12 2024-01-25 デュレクト コーポレーション 徐放性薬物送達システム及び関連の方法
KR20250003215A (ko) 2023-06-30 2025-01-07 주식회사 휴온스바이오파마 폴리솔베이트 20 및 세린을 포함하는 보툴리눔 독소의 안정화 액상 조성물
WO2025059665A1 (en) 2023-09-15 2025-03-20 Revance Therapeutics, Inc. Serial treatment with botulinum toxin for cervical dystonia
WO2025064729A1 (en) 2023-09-19 2025-03-27 Revance Therapeutics, Inc. Treatment with botulinum toxin in patients in need of a rapid onset cosmetic effect and smoother skin appearance
CN118697853B (zh) * 2024-06-27 2025-05-02 河北封章生物科技有限公司 一种稳定性提高的肉毒素制剂

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5625041A (en) * 1990-09-12 1997-04-29 Delta Biotechnology Limited Purification of proteins
US3269912A (en) * 1963-04-08 1966-08-30 Boehringer & Soehne Gmbh Aluminum oxide depot vaccines
US3758382A (en) * 1968-07-26 1973-09-11 Us Navy Ve agent process of freezing blood using a hydroxyalkyl starch as cryoprotecti
GB1514720A (en) * 1974-10-07 1978-06-21 Secr Defence Preparation of hydroxyethyl starch
DE2457047C3 (de) * 1974-12-03 1979-10-31 Behringwerke Ag, 3550 Marburg Verfahren zur Herstellung eines Derivates der leichten Kette des Tetanustoxins, dessen Verwendung zur Tetanusprophylaxe
NZ199722A (en) * 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
US4391801A (en) * 1981-10-29 1983-07-05 Cutter Laboratories, Inc. Plasma protein fraction substantially free of acetate ions
JPS5959625A (ja) * 1982-09-28 1984-04-05 Dainippon Pharmaceut Co Ltd ガン壊死因子を安定化する方法
US4457916A (en) * 1982-08-31 1984-07-03 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
HU188847B (en) * 1983-02-22 1986-05-28 Human Oltoanyagtermeloe Es Kutato Intezet,Hu Process for producing liophylized combined vaccines
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
JPS61161222A (ja) * 1985-01-09 1986-07-21 Takeda Chem Ind Ltd γ型インタ−フエロンフラグメントの組成物
EP0150067A3 (en) * 1984-01-23 1986-12-30 Takeda Chemical Industries, Ltd. Stable composition of gamma-interferon
JPS60258125A (ja) * 1984-06-06 1985-12-20 Hayashibara Biochem Lab Inc 蛋白性生理活性物質を含有する水溶性乾燥物
US4597966A (en) * 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
JPS61194034A (ja) * 1985-02-25 1986-08-28 Teijin Ltd 経鼻投与用粉末状組成物
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
DE3621828A1 (de) * 1986-06-28 1988-01-14 Biotest Pharma Gmbh Stabilisierung eines fuer therapeutische zwecke, insbesondere beim menschen, bestimmten interleukin-2-praeparates sowie dieses praeparat enthaltende stabilisierte waessrige loesung oder feststoff
JPH0696536B2 (ja) * 1988-02-26 1994-11-30 佐藤製薬株式会社 制酸剤含有内用懸濁液
JP2849632B2 (ja) * 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
FR2630115B1 (fr) * 1988-04-14 1994-10-28 Merieux Inst Procede de stabilisation des solutions d'albumine humaine et solution obtenue
FR2649991B2 (fr) † 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5919665A (en) * 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
US5945098A (en) * 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
AU7489091A (en) * 1990-03-01 1991-09-18 Agouron Pharmaceuticals, Inc. Enhanced cryopreservation with thermal hysteresis peptide
US5401243A (en) * 1990-08-21 1995-03-28 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
GB2255344B (en) * 1990-08-30 1994-07-20 Warner Lambert Co Composition comprising a hydrophilic polymer and a hydrophilic material different therefrom
US5695956A (en) * 1990-11-26 1997-12-09 University Of Pittsburgh Of The Commonwealth System Of Higher Education Clostridium perfingens type a enterotoxin toxoid and methods of preparation and use as a vaccine and therapeutic agent
JP2916947B2 (ja) * 1990-11-28 1999-07-05 興和株式会社 Ｃｐｂ―ｉの安定化方法及び製剤組成物
US5704297A (en) * 1991-02-06 1998-01-06 The Dupont Merck Pharmaceutical Company Dry powder composition of hydroxyethyl starch suitable for reconstitution
ES2109362T3 (es) * 1991-06-21 1998-01-16 Univ Cincinnati Unas proteinas administrables oralmente y metodo para hacerlas.
WO1993000807A1 (en) * 1991-07-03 1993-01-21 Cryolife, Inc. Method for stabilization of biomaterials
JPH0672891A (ja) * 1992-08-31 1994-03-15 Green Cross Corp:The ヒト血清アルブミン含有製剤
JP3510886B2 (ja) * 1992-06-23 2004-03-29 ボツリヌム トキシン リサーチ アソシエイト インコーポレイテッド ボツリヌスｂ複合体を含有する医薬組成物
US5445817A (en) * 1992-08-21 1995-08-29 The United States Of America As Represented By The Department Of Health And Human Services Pertussis toxin used as a carrier protein with non-charged saccharides in conjugate vaccines
US5728553A (en) * 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
EP0593176A3 (en) * 1992-09-28 1995-03-01 Wisconsin Alumni Res Found Pharmaceutical compositions containing botulinum toxin and method of manufacture.
US5466672A (en) * 1992-12-04 1995-11-14 Ophidian Pharmaceuticals, Inc. Therapeutic use of clostridium difficile toxin A
JP3007785B2 (ja) * 1993-03-16 2000-02-07 旭化成工業株式会社 トロンボモジュリン組成物およびその変性防止方法
US5562907A (en) * 1993-05-14 1996-10-08 Arnon; Stephen S. Method to prevent side-effects and insensitivity to the therapeutic uses of toxins
BR9406742A (pt) * 1993-06-04 1996-03-12 Biotime Inc Solução semelhante ao plasma
US5437291A (en) * 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
JP3533687B2 (ja) * 1993-12-17 2004-05-31 三菱ウェルファーマ株式会社 ヒト血清アルブミンの脱色方法
JP3684584B2 (ja) * 1993-12-17 2005-08-17 三菱ウェルファーマ株式会社 ヒト血清アルブミンの脱色方法
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
US5670484A (en) * 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
ES2238969T3 (es) * 1994-05-09 2005-09-16 William J. Binder Neurotoxinas presinapticas para el tratamiento de cefaleas migrañosas.
JPH07308199A (ja) † 1994-05-18 1995-11-28 Green Cross Corp:The ヒト血清アルブミンの製造方法
DE69531992T2 (de) * 1994-08-04 2004-07-22 Elan Drug Delivery Ltd., Ruddington Feste verabreichungssysteme zur gesteuerten freisetzung von darin eingebauten molekülen sowie verfahren zu deren herstellung
WO1996005222A1 (en) * 1994-08-08 1996-02-22 Wisconsin Alumni Research Foundation Purification and pharmaceutical compositions containing type g botulinum neurotoxin
US5756468A (en) * 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
US5512547A (en) * 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
ATE239491T1 (de) * 1995-06-06 2003-05-15 L Bruce Pearce Verbesserte zusammensetzungen und verfahren zur chemodenervation mit neurotoxinen
US5919463A (en) * 1995-07-07 1999-07-06 Oravax, Inc. Clostridium difficle toxins as mucosal adjuvants
JP3098401B2 (ja) * 1995-07-12 2000-10-16 株式会社エルティーティー研究所 経鼻投与用製剤
DE19538687A1 (de) * 1995-10-17 1997-04-24 Boehringer Mannheim Gmbh Stabile pharmazeutische Darreichungsformen enthaltend Parathormon
US5837265A (en) * 1996-03-08 1998-11-17 The Regents Of The University Of California Chemically-modified clostridiatoxin with improved properties
EP0889949B1 (en) * 1996-03-13 2003-05-28 Delta Biotechnology Limited Fermentation control
US5721215A (en) * 1996-03-20 1998-02-24 Allergan Injectable therapy for control of muscle spasms and pain related to muscle spasms
US5908825A (en) * 1997-01-09 1999-06-01 University Of Maryland At Baltimore Dosage composition for nasal delivery and method of use of the same
JPH10245400A (ja) * 1997-02-28 1998-09-14 Eiken Chem Co Ltd トランスフェリンレセプターの安定化方法
JPH10251161A (ja) * 1997-03-11 1998-09-22 Green Cross Corp:The 浮腫治療効果増強剤
US6210683B1 (en) * 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
US6051239A (en) * 1997-10-20 2000-04-18 Thomas Jefferson University Compositions and methods for systemic delivery of oral vaccines and therapeutic agents
ATE220558T1 (de) * 1997-11-22 2002-08-15 Roche Diagnostics Gmbh Verbessertes verfahren zur stabilisierung von proteinen
US6346519B1 (en) * 1998-09-09 2002-02-12 Advanced Medical Instruments Method and composition for treating arthritis
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
US6358917B1 (en) * 1999-08-24 2002-03-19 Jean D. A. Carruthers Cosmetic use of botulinum toxin for treatment of downturned mouth
US6113915A (en) * 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6139845A (en) * 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US6337075B1 (en) * 2000-01-11 2002-01-08 Allergan Sales, Inc. Methods for treating diabetes
JP2003522154A (ja) * 2000-02-08 2003-07-22 アラーガン、インコーポレイテッド ボツリヌス毒素医薬組成物
JP2003009897A (ja) * 2001-07-03 2003-01-14 Keiji Oguma ボツリヌス毒素の分離・精製法
MXPA01011542A (es) * 2001-11-13 2003-05-22 Alcon Inc Regeneracion del cartilago articular da°ado por la osteoartritis de grado i y ii, mediante la aplicacion intra-articular de una mezcla de hialuronato de sodio y de condroitin sulfato en un vehiculo de gel.

Also Published As

Publication number Publication date
TWI317283B (en) 2009-11-21
CA2400318A1 (en) 2001-08-16
JP2005336201A (ja) 2005-12-08
JP2003522154A (ja) 2003-07-22
NZ530779A (en) 2004-08-27
ES2275992T5 (es) 2011-05-18
JP2007332155A (ja) 2007-12-27
EP1514556A1 (en) 2005-03-16
JP5080902B2 (ja) 2012-11-21
JP2011251988A (ja) 2011-12-15
CA2494241C (en) 2011-06-14
DE60110372T2 (de) 2006-01-19
PT1514556E (pt) 2011-09-08
DE60110372D1 (de) 2005-06-02
DK1253932T3 (da) 2005-06-27
ATE519494T1 (de) 2011-08-15
KR20020084115A (ko) 2002-11-04
TWI282739B (en) 2007-06-21
AU2001233315B2 (en) 2004-07-08
WO2001058472A3 (en) 2002-01-03
NZ520201A (en) 2004-04-30
EP1253932A2 (en) 2002-11-06
EP1398038B1 (en) 2007-01-10
CA2478621C (en) 2006-11-21
JP4118830B2 (ja) 2008-07-16
DE60125986T3 (de) 2011-07-28
AR027391A1 (es) 2003-03-26
CA2494241A1 (en) 2001-08-16
KR20060090938A (ko) 2006-08-17
CN1331532C (zh) 2007-08-15
CA2478621A1 (en) 2001-08-16
EP1253932B1 (en) 2005-04-27
CA2400318C (en) 2005-06-14
DK1398038T3 (da) 2007-04-02
US20080213315A1 (en) 2008-09-04
JP2005179375A (ja) 2005-07-07
CN1616084A (zh) 2005-05-18
MXPA02007519A (es) 2004-10-15
EP1398038B2 (en) 2011-01-26
EP1586329A1 (en) 2005-10-19
PT1398038E (pt) 2007-02-28
ES2237551T3 (es) 2005-08-01
JP2004256545A (ja) 2004-09-16
EP1514556B1 (en) 2011-08-10
US20020064536A1 (en) 2002-05-30
PT1253932E (pt) 2005-07-29
JP2012031194A (ja) 2012-02-16
BR0108173A (pt) 2003-01-21
KR100753765B1 (ko) 2007-08-31
ES2368061T3 (es) 2011-11-14
CN1258379C (zh) 2006-06-07
CN1398188A (zh) 2003-02-19
WO2001058472A2 (en) 2001-08-16
TW200711657A (en) 2007-04-01
DK1514556T3 (da) 2011-10-24
KR20060028475A (ko) 2006-03-29
EP1398038A1 (en) 2004-03-17
ES2275992T3 (es) 2007-06-16
DE60125986D1 (de) 2007-02-22
KR100665469B1 (ko) 2007-01-04
KR100799400B1 (ko) 2008-01-30
AU3331501A (en) 2001-08-20
DE60125986T2 (de) 2007-10-18
DK1398038T4 (da) 2011-03-28
CY1108007T1 (el) 2013-09-04

Similar Documents

Publication Publication Date Title
ATE519494T1 (de) Pharmazeutische zusammensetzungen mit botulinum- toxin
DE60142197D1 (de) Pharmazeutische Zusammensetzung
ATE320244T1 (de) Pharmazeutische zusammensetzungen mit amlodipinmaleat
ATE279961T1 (de) Neue pharmazeutische zusammensetzung
ITTO20010008A0 (it) Formulazione farmaceutica
AR028204A1 (es) Composiciones farmaceuticas electrohiladas
FI20105657L (fi) Farmaseuttisia koostumuksia
ITMI20010748A0 (it) Composizioni farmaceutiche
NO20025450L (no) Ny farmasöytisk sammensetning
DE60213592D1 (de) Flüssige pharmazeutische zusammensetzung
NO20026123L (no) Farmasöytiske sammensetninger
DE60129238D1 (de) Pharmazeutische zusammensetzung
ATE350016T1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
EP1124557A4 (en) Pharmaceutical composition
DE10291905D2 (de) Pharmazeutische Zusammensetzung
ATE350029T1 (de) Pharmazeutische zusammensetzung enthaltend gamma- butyrobetain
MXPA03001857A (es) Composicones medicinales.
DE10107261B4 (de) Pharmazeutische Zusammensetzung
EE200200689A (et) Ravimkoostised

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1253932

Country of ref document: EP